Cargando…

The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world

BACKGROUND: Blood eosinophil measurements may help to guide physicians on the use of inhaled corticosteroids (ICS) for patients with chronic obstructive pulmonary disease (COPD). Emerging data suggest that COPD patients with higher blood eosinophil counts may be at higher risk of exacerbations and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Neil, Ishii, Takeo, Hizawa, Nobuyuki, Midwinter, Dawn, James, Mark, Hilton, Emma, Jones, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799851/
https://www.ncbi.nlm.nih.gov/pubmed/29440882
http://dx.doi.org/10.2147/COPD.S144108
_version_ 1783298083529949184
author Barnes, Neil
Ishii, Takeo
Hizawa, Nobuyuki
Midwinter, Dawn
James, Mark
Hilton, Emma
Jones, Paul W
author_facet Barnes, Neil
Ishii, Takeo
Hizawa, Nobuyuki
Midwinter, Dawn
James, Mark
Hilton, Emma
Jones, Paul W
author_sort Barnes, Neil
collection PubMed
description BACKGROUND: Blood eosinophil measurements may help to guide physicians on the use of inhaled corticosteroids (ICS) for patients with chronic obstructive pulmonary disease (COPD). Emerging data suggest that COPD patients with higher blood eosinophil counts may be at higher risk of exacerbations and more likely to benefit from combined ICS/long-acting beta(2)-agonist (LABA) treatment than therapy with a LABA alone. This analysis describes the distribution of blood eosinophil count at baseline in Japanese COPD patients in comparison with non-Japanese COPD patients. METHODS: A post hoc analysis of eosinophil distribution by percentage and absolute cell count was performed across 12 Phase II–IV COPD clinical studies (seven Japanese studies [N=848 available absolute eosinophil counts] and five global studies [N=5,397 available eosinophil counts] that included 246 Japanese patients resident in Japan with available counts). Blood eosinophil distributions were assessed at baseline, before blinded treatment assignment. FINDINGS: Among Japanese patients, the median (interquartile range) absolute eosinophil count was 170 cells/mm(3) (100–280 cells/mm(3)). Overall, 612/1,094 Japanese patients (56%) had an absolute eosinophil count ≥150 cells/mm(3) and 902/1,304 Japanese patients (69%) had a percentage eosinophil ≥2%. Among non-Japanese patients, these values were 160 (100–250) cells/mm(3), 2,842/5,151 patients (55%), and 2,937/5,155 patients (57%), respectively. The eosinophil distribution among Japanese patients was similar to that among non-Japanese patients. Within multi-country studies with similar inclusion criteria, the eosinophil count was numerically lower in Japanese compared with non-Japanese patients (median 120 vs 160 cells/mm(3)). INTERPRETATION: The eosinophil distribution in Japanese patients seems comparable to that of non-Japanese patients; although within multi-country studies, there was a slightly lower median eosinophil count for Japanese patients compared with non-Japanese patients. These findings suggest that blood eosinophil data from global studies are of relevance in Japan.
format Online
Article
Text
id pubmed-5799851
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57998512018-02-13 The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world Barnes, Neil Ishii, Takeo Hizawa, Nobuyuki Midwinter, Dawn James, Mark Hilton, Emma Jones, Paul W Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Blood eosinophil measurements may help to guide physicians on the use of inhaled corticosteroids (ICS) for patients with chronic obstructive pulmonary disease (COPD). Emerging data suggest that COPD patients with higher blood eosinophil counts may be at higher risk of exacerbations and more likely to benefit from combined ICS/long-acting beta(2)-agonist (LABA) treatment than therapy with a LABA alone. This analysis describes the distribution of blood eosinophil count at baseline in Japanese COPD patients in comparison with non-Japanese COPD patients. METHODS: A post hoc analysis of eosinophil distribution by percentage and absolute cell count was performed across 12 Phase II–IV COPD clinical studies (seven Japanese studies [N=848 available absolute eosinophil counts] and five global studies [N=5,397 available eosinophil counts] that included 246 Japanese patients resident in Japan with available counts). Blood eosinophil distributions were assessed at baseline, before blinded treatment assignment. FINDINGS: Among Japanese patients, the median (interquartile range) absolute eosinophil count was 170 cells/mm(3) (100–280 cells/mm(3)). Overall, 612/1,094 Japanese patients (56%) had an absolute eosinophil count ≥150 cells/mm(3) and 902/1,304 Japanese patients (69%) had a percentage eosinophil ≥2%. Among non-Japanese patients, these values were 160 (100–250) cells/mm(3), 2,842/5,151 patients (55%), and 2,937/5,155 patients (57%), respectively. The eosinophil distribution among Japanese patients was similar to that among non-Japanese patients. Within multi-country studies with similar inclusion criteria, the eosinophil count was numerically lower in Japanese compared with non-Japanese patients (median 120 vs 160 cells/mm(3)). INTERPRETATION: The eosinophil distribution in Japanese patients seems comparable to that of non-Japanese patients; although within multi-country studies, there was a slightly lower median eosinophil count for Japanese patients compared with non-Japanese patients. These findings suggest that blood eosinophil data from global studies are of relevance in Japan. Dove Medical Press 2018-02-02 /pmc/articles/PMC5799851/ /pubmed/29440882 http://dx.doi.org/10.2147/COPD.S144108 Text en © 2018 Barnes et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Barnes, Neil
Ishii, Takeo
Hizawa, Nobuyuki
Midwinter, Dawn
James, Mark
Hilton, Emma
Jones, Paul W
The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title_full The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title_fullStr The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title_full_unstemmed The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title_short The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world
title_sort distribution of blood eosinophil levels in a japanese copd clinical trial database and in the rest of the world
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799851/
https://www.ncbi.nlm.nih.gov/pubmed/29440882
http://dx.doi.org/10.2147/COPD.S144108
work_keys_str_mv AT barnesneil thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT ishiitakeo thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT hizawanobuyuki thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT midwinterdawn thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT jamesmark thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT hiltonemma thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT jonespaulw thedistributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT barnesneil distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT ishiitakeo distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT hizawanobuyuki distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT midwinterdawn distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT jamesmark distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT hiltonemma distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld
AT jonespaulw distributionofbloodeosinophillevelsinajapanesecopdclinicaltrialdatabaseandintherestoftheworld